Skip to main content Help with accessibility Skip to main navigation

UPADACITINIB prolonged-release tablets (RINVOQ®▼) for treating moderate rheumatoid arthritis

CCG Approval Status:

Ha
Kn
Li
SF
SS
SH
Wa
WL
Wi
Date Added: 10 - Feb - 2021
Body System:
Grey
UPADACITINIB prolonged-release tablets (RINVOQ®▼) for treating moderate rheumatoid arthritis

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of UPADACITINIB prolonged-release tablets (RINVOQ®▼) for treating moderate rheumatoid arthritis.